文献

J-GLOBAL ID：201602281323885509   整理番号：16A1212651

リツキシマブ治療が奏功した心筋症を伴うTAFRO症候群患者

Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy

著者 (14件)： HIRAMATSU Sumie (Department of Rheumatology and Clinical Immunology) ,  OHMURA Koichiro (Department of Rheumatology and Clinical Immunology) ,  TSUJI Hideaki (Department of Rheumatology and Clinical Immunology) ,  KAWABATA Hiroshi (Department of Hematology/Oncology) ,  KITANO Toshiyuki (Department of Hematology/Oncology) ,  SOGABE Ayuko (Department of Rheumatology and Clinical Immunology) ,  HASHIMOTO Motomu (Department of the Control for Rheumatic Diseases, Kyoto University Graduate School of Medicine) ,  MURAKAMI Kosaku (Department of Rheumatology and Clinical Immunology) ,  IMURA Yoshitaka (Department of Rheumatology and Clinical Immunology) ,  YUKAWA Naoichiro (Department of Rheumatology and Clinical Immunology) ,  YOSHIFUJI Hajime (Department of Rheumatology and Clinical Immunology) ,  FUJII Takao (Department of the Control for Rheumatic Diseases, Kyoto University Graduate School of Medicine) ,  TAKAORI-KONDO Akifumi (Department of Hematology/Oncology) ,  MIMORI Tsuneyo (Department of Rheumatology and Clinical Immunology)
資料名： 日本臨床免疫学会会誌  (Japanese Journal of Clinical Immunology)
巻： 39  号： 1  ページ： 64-71(J-STAGE)  発行年： 2016年 
JST資料番号： X0337A  ISSN： 0911-4300  資料種別： 逐次刊行物 (A)
記事区分： 短報  発行国： 日本 (JPN)  言語： 英語 (EN)

抄録/ポイント： Castleman-Kojima病(TAFRO症候群)は血小...

シソーラス用語： *モノクローナル抗体 ,...
準シソーラス用語： Castleman病 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A1212651&from=J-GLOBAL&jstjournalNo=X0337A") }}

著者キーワード (5件)： TAFRO syndrome ,  Castleman’s disease ,  rituximab ,  cardiomyopathy ,  tocilizumab

分類 (3件)： 血液疾患の薬物療法  (GK05020P) ,  免疫療法薬・血液製剤の臨床への応用  (GW22020O) ,  循環系の臨床医学一般  (GJ01030V)

引用文献 (21件)：

• 1) Kawabata, H., et al.: Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). Journal of clinical and experimental hematopathology. 53: 57-61, 2013.
• 2) Inoue, M., et al.: Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. Journal of clinical and experimental hematopathology. 53: 95-99, 2013.
• 3) Iwaki, N., et al.: Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. Journal of clinical and experimental hematopathology. 53: 87-93, 2013.
• 4) Kawabata, H., et al.: Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Internal medicine (Tokyo, Japan), 52: 1503-1507, 2013.
• 5) Masaki, Y., et al.: Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia - a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? Journal of clinical and experimental hematopathology. 53: 79-85, 2013.

タイトルに関連する用語 (5件)： リツキシマブ ,  治療 ,  心筋症 ,  TAFRO症候群 ,  患者